



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY ¹

Last Trade:	82.53
Trade Time:	1:08 PM ET 06.26.2017
Change:	-2.68 (3.145%)
Day Range	80.58 - 85.76
52-Week Range	31.38 - 86.92
Volume	549,093
Market Cap. (\$M)	7,550.670
Shares Out (M)	91.490

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

06.26.2017

[Alnylam Reports New Positive Clinical Results for Givosiran \(ALN-AS1\), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias](#)

06.19.2017

[Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term](#)

06.12.2017

[Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office](#)

06.07.2017

[Alnylam Expands Third Annual "Helping Hands" Community Service Day Globally to Benefit 18 Organizations](#)

05.31.2017

[FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

02.15.2017

[Annual Report \(10-K\)](#)

03.17.2017

[Definitive Proxy Statement](#)

05.05.2017

[Quarterly Report \(10-Q\)](#)

11.03.2016

[Quarterly Report \(10-Q\)](#)

08.04.2016

[Quarterly Report \(10-Q\)](#)